表紙
市場調查報告書

拉薩熱:開發中產品分析

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 363115
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
拉薩熱:開發中產品分析 Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 58 Pages
簡介

本報告提供拉薩熱治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

拉薩熱概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

拉薩熱:企業開發中的治療藥

拉薩熱:大學/機關研究中的治療藥

拉薩熱:開發中產品概況

  • 初期階段的產品

拉薩熱:企業開發中的產品

拉薩熱:大學/機關研究中的產品

rassa環境熱能治療藥的開發企業

  • Arno Therapeutics, Inc.
  • Celgene Corporation
  • Etubics Corporation
  • Kineta, Inc.
  • Profectus BioSciences, Inc.
  • SIGA Technologies, Inc.

拉薩熱:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

拉薩熱:暫停中的計劃

拉薩熱:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11553IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever - Pipeline Review, H2 2019, provides an overview of the Lassa Fever (Infectious Disease) pipeline landscape.

Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arena virus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes and bleeding.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lassa Fever - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Lassa Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lassa Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Lassa Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Lassa Fever (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Lassa Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Lassa Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Lassa Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Lassa Fever (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Lassa Fever (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Lassa Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lassa Fever (Lassa Hemorrhagic Fever) - Overview
  • Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Lassa Fever (Lassa Hemorrhagic Fever) - Companies Involved in Therapeutics Development
    • Emergent BioSolutions Inc
    • Etubics Corp
    • Fujifilm Toyama Chemical Co Ltd
    • GeoVax Labs Inc
    • Inovio Pharmaceuticals Inc
    • Kineta Inc
    • Medigen Inc
    • RetroVirox Inc
    • Themis Bioscience GmbH
    • Zalgen Labs LLC
  • Lassa Fever (Lassa Hemorrhagic Fever) - Drug Profiles
    • (Lassa fever + rabies) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • arevirumab-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • favipiravir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GEOLM-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hemorrhagic fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-4500 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lassa fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lassa vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LHF-535 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ML-29 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Lassa Fever - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-193 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects
  • Lassa Fever (Lassa Hemorrhagic Fever) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 30, 2019: Themis Bioscience and CEPI trial Lassa fever vaccine
      • Aug 06, 2019: Kineta Secures $1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535
      • Jul 16, 2019: GeoVax announces upcoming presentation of lassa fever vaccine data
      • Jul 15, 2019: Kineta secures NIAID grant worth up to $5.8M to evaluate LHF-535 in Arenaviruses
      • May 23, 2019: Inovio doses patients in Phase I trial of Lassa virus vaccine INO-4500
      • Dec 11, 2018: Batavia Biosciences Partners with IAVI to Advance Development of Vaccine Against Lassa Fever
      • Sep 26, 2018: GeoVax awarded $2.4 million from U.S. Department of Defense to advance Lassa Fever Vaccine
      • Sep 05, 2018: Kineta initiates first-in-human clinical trial of LHF-535 a novel therapy for lassa fever
      • Aug 20, 2018: Emergent and Profectus receive CEPI contract for Lassa virus vaccine
      • Jun 27, 2018: NIAID Scientists Recommend Favipiravir for Human Trials of Lassa Fever Virus
      • Apr 10, 2018: GeoVax Awarded NIH Fast Track Phase I/II Grant to Advance Lassa Fever Vaccine
      • Oct 24, 2017: Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study
      • Jul 24, 2017: GeoVax Joins with Scripps Research Institute and Institute of Human Virology at University of Maryland School of Medicine to Develop Lassa Fever Vaccine
      • Jul 11, 2017: Tulane University awarded $12 million to create Lassa vaccine and treatment
      • Jul 10, 2017: GeoVax Reports Promising Results for Lassa Fever Vaccine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 4: Products under Development by Companies, H2 2019
  • Table 5: Products under Development by Universities/Institutes, H2 2019
  • Table 6: Number of Products by Stage and Target, H2 2019
  • Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 8: Number of Products by Stage and Route of Administration, H2 2019
  • Table 9: Number of Products by Stage and Molecule Type, H2 2019
  • Table 10: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, H2 2019
  • Table 11: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Etubics Corp, H2 2019
  • Table 12: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Fujifilm Toyama Chemical Co Ltd, H2 2019
  • Table 13: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by GeoVax Labs Inc, H2 2019
  • Table 14: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Inovio Pharmaceuticals Inc, H2 2019
  • Table 15: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Kineta Inc, H2 2019
  • Table 16: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Medigen Inc, H2 2019
  • Table 17: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by RetroVirox Inc, H2 2019
  • Table 18: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Themis Bioscience GmbH, H2 2019
  • Table 19: Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Zalgen Labs LLC, H2 2019
  • Table 20: Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Targets, H2 2019
  • Figure 5: Number of Products by Stage and Targets, H2 2019
  • Figure 6: Number of Products by Routes of Administration, H2 2019
  • Figure 7: Number of Products by Stage and Routes of Administration, H2 2019
  • Figure 8: Number of Products by Molecule Types, H2 2019
  • Figure 9: Number of Products by Stage and Molecule Types, H2 2019
Back to Top